Agoracom Blog Home

Posts Tagged ‘$TSXV’

Bougainville $BOG.ca Signs Binding LOI to Acquire Assets of Gene Bank Research Inc. $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 4:31 PM on Thursday, November 1st, 2018

681747 5720 copy 2

  • Entering the Canadian cannabis market through the signing of a binding Letter of Intent to acquire the assets and inventory of Gene Bank Research Inc.,
  • Places Bougainville in a strong position to capitalize on the market opportunities created by the new Cannabis Act.

VANCOUVER, British Columbia, Nov. 01, 2018 — BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company“) (CSE:BOG) is pleased to announce that it has entered the Canadian cannabis market through the signing of a binding Letter of Intent to acquire the assets and inventory of Gene Bank Research Inc., placing Bougainville in a strong position to capitalize on the market opportunities created by the new Cannabis Act.

About Gene Bank Research Inc.
Gene Bank has over 110 lab-tested craft strains developed by its team of knowledgeable breeders possessing over 17 years’ experience.  These unique craft strains allow licensed producers to stand out in an increasingly generic and homogenized market.

The Gene Bank assets include:

  • Seeds – a collection of many of the building block genetics of today’s top ranked strains from around the world and used by top breeders
  • Clones – the healthiest genetic selections based on specific phenotype/genotype characteristics
  • Adult Plants – thousands of plants grown out to select the strongest, healthiest, highest yielding and disease/mold resistance available
  • Graphed plants – unique super strains created by graphing the industry’s hardiest strains with weaker more finicky varieties

Principle LOI Terms

  • Binding LOI
  • Transfer of 100% of Gene Bank’s assets and current inventory to Bougainville
  • Payment of $5,000,000 of Bougainville shares, with the price of such BOG shares to be based on 5 day volume weighted average price (“VWAP”) by reference to October 30, 2018
  • Assets include:
    • Seeds
    • Genetic Lab Reports
    • All Proprietary Information
    • Bank Accounts
    • Business Deck
    • Corporation Documents

CEO, Andy Jagpal Comments:
“The acquisition of Gene Bank greatly expands our reach through vertical integration with the ability to provide unique and highly valued strains of seeds and clones to the cannabis market. I am confident this acquisition can substantially enhance Bougainville’s market value.”

About Bougainville Ventures, Inc. 
Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost.

For more information please visit: http://bougainvilleinc.com/

On behalf of the Board of Directors
BOUGAINVILLE VENTURES INC.

Andy Jagpal, CEO and Director

For further information, please contact Andy Jagpal at [email protected] or 1-844-734-8420 

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws, including statements regarding the Oroville, WA cultivation facility: statements pertaining to the ability of Bougainville Ventures Inc. (“BOG”); the anticipated economic potential of the property; the availability of capital and finance for BOG to execute its strategy going forward. Forward-looking statements are based on estimates and assumptions made by BOG in light of its experience and perception of current and expected future developments, as well as other factors that BOG believes are appropriate in the circumstances. Many factors could cause BOG’s results, performance or achievements to differ materially from those expressed or implied by the forward looking statements, including: discrepancies between actual and estimated results from exploration and development and operating risks, dependence on early exploration stage concessions; uninsurable risks; competition; regulatory restrictions, including environmental regulatory restrictions and liability; currency fluctuations; defective title to mineral claims or property and dependence on key employees. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the information contained in this news release.

A Social Network You Can Make a Living From #Peeks $PEEK.ca $IDK.ca $BCOV $AVID

Posted by AGORACOM-JC at 9:35 AM on Thursday, November 1st, 2018

Peeks dark logo

Peeks Social has a social network that you can make a living from.

Peeks Social is a live-streaming social network which enables social and commercial interactions, Peer-to-Peer payments, and other social commerce capabilities. Peeks Social is the world’s first social network which bridges the gap between traditional social media and professionally produced content via live or pre-recorded broadcasts. Peeks Social enables content creators to immediately monetize their content through patented and proprietary payment technologies.

The Most Rewarding Live Streaming Platform

Go Live
Start broadcasting your stream from anywhere to anyone in the world.

Get Paid
Collect tips, get sponsored, use paywalls and get paid for your content.

Get Popular
Grow your followers overnight by getting featured in Peeks Social.

Explore
Watch exclusive live streams and videos from around the world and receive special offers.

For more information on Peeks Social Ltd. (PEEK:TSX.V) please fill out the form below.

Source: https://www.b-tv.com/peeks-social-company-feature-ep-332/

Tetra Bio-Pharma $TBP.ca Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001 $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:57 AM on Thursday, November 1st, 2018

Logo tetrabiopharma rgb web

  • Announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.
  • This represents the first ever human clinical trial featuring a vaporized cannabinoid drug product 

OTTAWA, Nov. 01, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.

This study aims to determine the Pharmacokinetic and safety profile of PPP001 delivered as an inhaled vapour using the Mighty Medic (see previous July 16, 2018 News Release), thus providing patients with an alternative to the smoked version of PPP001 and allowing Tetra to develop PPP001 for healthier patients suffering from uncontrolled pain.   It is anticipated that this phase 1 data, combined with Tetra’s characterization of the composition of vapor, will provide the necessary evidence to advance the development of vaporized PPP001 into more chronic and non-life-threatening diseases, such as fibromyalgia. The study is expected to begin and end in Q4 2018.

“We are pleased to announce this critical Phase 1 trial focused on the PK and safety of our PPP001 pellet delivered by vaporization,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc. “Over the last 3 months we have analyzed the composition of the vapor.  This data combined with the results of this Phase 1 will provide the critical pharmacological information required by physicians to adequately guide future efficacy studies in patients who suffer from a chronic condition such as fibromyalgia where there are limited treatment options and there is a large unmet medical need.  It may also provide an alternative mode of delivery for those patients who prefer not to smoke.”

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.  For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

 

Tetra $TBP.ca Natural Health Signs Exclusive Agreement for the Distribution of their #Hemp Energy Drink in Canada and the USA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:55 AM on Thursday, November 1st, 2018

Logo tetrabiopharma rgb web

  • Announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink
  • In the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.

Tetra Natural Health Looking to Exploit Consumer Appetite for Hemp Based products

OTTAWA, Nov. 01, 2018 – Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.

The Hemp Energy Drink provides consumers with a product that contains fewer calories and more natural ingredients than existing energy drinks thus providing a welcome alternative to existing products in what is considered to be an extremely lucrative market.

“We are thrilled in having signed this agreement with Kombucha Baby and its distribution partners providing Tetra Natural Health with access to a significant number of retail outlets in both Canada and the USA,” stated Richard Giguere, CEO of Tetra Natural Health.

“We are very excited to be adding the Hemp Energy Drink to our portfolio of products that will be available to our existing and potential client base,” stated Dan McKenna, President and CEO of Kombucha Baby Brewing Company Inc. “Numerous Canadian and U.S. customers representing thousands of retail outlets have indicated a strong interest in carrying this unique Natural Health Product (NHP).”

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]

Stephanie Engel
416-425-9143 ext. 209
[email protected]

VIDEO: Northbud $NBUD.ca October Construction Update $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 4:49 PM on Wednesday, October 31st, 2018

Northbud large

NORTHBUD October Construction Update. Everything is on schedule!

Hub On AGORACOM / Corporate Profile

UpGrad acquires job skilling startup Acadview #India #edtech $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 2:22 PM on Wednesday, October 31st, 2018

UpGrad, promoted by entrepreneur Ronnie Screwvala, aims to extend its online learning platform to the undergraduate level through the Acadview acquisition

  • Acadview marks Upgrad’s second acquisition in two years
  • Recent transaction marks Upgrad’s second acquisition in two years. It is looking to capture a large chunk of the $20 billion education market in India
Ronnie Screvwala. Acadview marks Upgrad’s second acquisition in two years. It is looking to capture a large chunk of the $20 billion education market in India. Photo: Abhijit Bhatlekar/Mint

New Delhi: Online education startup UpGrad has acquired job skilling platform Acadview Software Pvt. Ltd for an undisclosed sum, UpGrad said in a statement on Monday. UpGrad, promoted by entrepreneur Ronnie Screwvala, aims to extend its online learning platform to the undergraduate level through the acquisition.

Founded in early 2015, Acadview seeks to upskill graduates with in-demand technologies through live online courses and industry projects, enabling better employment opportunities. It claims to have trained more than 3,000 students in 2017.

“UpGrad’s highly engaging online learning solution along with Acadview’s solid presence within the college space in India will allow us to deploy learning solution for college students at a massive scale,” said Screwvala and Mayank Kumar, co-founders at UpGrad, in a joint statement.

Gurugram-based Acadview had raised an undisclosed amount of funding from angel investors in India and the Silicon Valley. It has also partnered with over 80 universities and colleges in north India.

“Equipping students with engaging content, personalized coaching, hands-on experience with real world projects and guidance from subject matter experts in the industry can bring a step change in the quality of workforce available to employers.We believe in UpGrad’s vision, and feel that we have found a perfect cultural fit for our mission,” said Himanshu Batra, founder and chief executive at Acadview.

The recent transaction marks Upgrad’s second acquisition in two years. It is looking to capture a large chunk of the $20 billion education market in India.

Founded by Screwvala, Kumar, Phalgun Kompalli and Ravijot Chugh, UpGrad offers online courses in entrepreneurship, digital marketing and data analytics, among others, for working professionals.

UpGrad competes with foreign online education start-ups, including Coursera and Udacity, and home-grown ventures such as EduReka and Simplilearn.

Mint reported in October 2017 that UpGrad is also looking at to enter foreign markets in West Asia and South East Asia, and had committed ₹300 crore to fund the expansion. The corpus is three times the amount it had invested in the Indian market.

Source: https://www.livemint.com/Companies/If8GzLkcRMUwA5W0D0r1CL/UpGrad-acquires-job-skilling-startup-Acadview.html

#Gold industry sees prices rising to $1,532/oz over 12 months $AMK.ca $EXS.ca $MQR.ca $GDX.ca $ECR.ca $MZZ.ca $QMX.ca $IMG.ca $IAG $MUX

Posted by AGORACOM-JC at 10:47 AM on Wednesday, October 31st, 2018
  • The price of gold is expected to rise to $1,532 an ounce by October next year, delegates to the London Bullion Market Association’s annual gathering predicted on Tuesday
  • A poll of delegates at the LBMA conference in Boston also predicted higher prices in a year’s time for silver, platinum and palladium.

BOSTON, Oct 30 (Reuters) – The price of gold is expected to rise to $1,532 an ounce by October next year, delegates to the London Bullion Market Association’s annual gathering predicted on Tuesday.

A poll of delegates at the LBMA conference in Boston also predicted higher prices in a year’s time for silver, platinum and palladium.

Spot gold has had a difficult few months, falling from a high of $1,366.07 in January to as low as $1,159.96 in August as the dollar strengthened and the U.S. Federal Reserve pushed ahead with interest rate rises.

But it has since clawed back to around $1,225 an ounce as volatility on global stock markets revived interest in bullion as a safe place to store assets.

A stronger dollar hurts gold prices by making it more expensive for buyers with other currencies. Higher interest rates make gold, which offers no yield, less attractive.

The poll also showed that delegates expect silver prices to rise to $15 an ounce by the end of October 2019 from around $14.50 on Tuesday.

Platinum prices were forecast to increase to $1,010 an ounce over the next year from around $835 on Tuesday and palladium was expected to rise to $1,195 from around $1,075.

Analysts and traders polled by Reuters this month said they expected gold prices to average $1,300 an ounce in 2019, silver to average $16.40, platinum to average $875 and palladium to average $1,025.

Source: https://uk.reuters.com/article/gold-lbma-price/gold-industry-sees-prices-rising-to-1532-oz-over-12-months-idUKL8N1X55VR

Microsoft $MSFT to Integrate #Blockchain Offering Into #Nasdaq Services Following New Partnership $IDK.ca $HIVE.ca $BLOC.ca $CODE.ca

Posted by AGORACOM-JC at 10:00 AM on Wednesday, October 31st, 2018

  • American software corporation Microsoft will integrate its Azure Blockchain technology into stock exchange Nasdaq Inc.’s Financial Framework (NFF), according to an Oct. 30 press release.
  • Per the recent announcement, Microsoft will integrate its Azure blockchain service with NFF, a technology which provides software for trading infrastructure and operations outsourcing, and fulfills Nasdaq’s risk and surveillance technology offering.

Within the collaboration, the parties will reportedly develop a “ledger agnostic blockchain capability” that will allow for operability across multiple ledgers. The new product will purportedly facilitate easier buyer and seller matching, management of delivery, and payment and settlement of transactions.

Integrating Azure Blockchain will reportedly allow NFF customers to deploy various blockchains through one common interface, in addition to promoting blockchain development.

Tom Fay, Senior Vice President of Enterprise Architecture at Nasdaq, said that the partnership with Microsoft removes some of the complexities of integrating blockchain technology into existing infrastructures. He added:

“Our NFF integration with their blockchain services provides a layer of abstraction, making our offering ledger-agnostic, secure, highly scalable, and ultimately helps us continue to explore a much broader range of customer use cases for blockchain.”

Recently, Nasdaq revealed a new blockchain patent, which makes reference to “an information computer system […] provided for securely releasing time-sensitive information to recipients via a blockchain.” With the patent, the company is reportedly looking to ease releasing timely information to the media while keeping it secure and watertight from a legal standpoint.

Last month in an interview with Cointelegraph, Nasdaq’s Head of Alternative Data Bill Dague said that it is exploring adding crypto datasets to its market analytics tool. However, whether or not the exchange will launch a crypto-related product remains to be seen.

In August, Azure introduced a proof-of-authority (PoA) algorithm on its Ethereum blockchain product. A PoA algorithm is based on the principle of approved identities or validators on a blockchain, and does not require competition in completing the transactions.

The new Ethereum product on Azure is equipped with a number of features to ensure its correct functioning and security, such as an identity leasing system, Parity’s web-assembly support, Azure Monitor, and a Governance Decentralized Application (DApp).

Source: https://cointelegraph.com/news/microsoft-to-integrate-blockchain-offering-into-nasdaq-services-following-new-partnership

Peeks Social $PEEK.ca Announces Financial Results for Q2 Ended August 31, 2018 With Gross Revenue of $2.1 million $IDK.ca $BCOV $AVID

Posted by AGORACOM-JC at 8:42 AM on Wednesday, October 31st, 2018

Peeks dark logo

  • The Peeks Social platform generated gross revenue of $2.1 million during Q2 2019, up from $1.3 million during Q2 2018;
  • User sessions were 6.50 million for the three months ended August 31, 2018, as compared to 4.63 million for the three months ended August 31, 2017

TORONTO, Oct. 31, 2018 — Peeks Social Ltd. (TSXV: PEEK; OTCQB: PKSLF) (“Peeks Social” or the “Company”) announced that the unaudited condensed consolidated interim financial statements (“Financial Statements”) and Management’s Discussion and Analysis (“MD&A”) for the three and six months ended August 31, 2018 (“Q2 2019”), are now available on the Company’s profile on SEDAR (www.sedar.com). The three months ended August 31, 2018, represent the second quarter of the Company’s 2019 fiscal year.

It is important to note that this is the second reporting period of the Company following the completion of the acquisition of Personas.com Corporation (“Personas”) in May 2018 (see press release dated May 8, 2018). As the acquisition of Personas constituted a reverse acquisition, the Financial Statements are a continuation of the financial statements of Personas, and the comparative results are those of Personas, prior to the acquisition. Due to a change in the year end of Personas, the comparative results represent the three (“Q2 2018”) and eight months ended August 31, 2017, which should be taken into account when reviewing comparative numbers.

Select quarterly highlights include the following:

  • The Peeks Social platform generated gross revenue of $2.1 million during Q2 2019, up from $1.3 million during Q2 2018;
  • GAAP net loss increased to $1.6 million in Q2 2019 from $1.4 million in Q2 2018;
  • GAAP net loss per share was $0.007 for Q2 2019 as compared to $0.012 for Q2 2018; and
  • User sessions were 6.50 million for the three months ended August 31, 2018, as compared to 4.63 million for the three months ended August 31, 2017 (and as compared to 6.20 million for the three months ended May 31, 2018).

Certain information provided in this news release is extracted from the unaudited condensed consolidated interim Financial Statements and MD&A of the Company for the three and six months ended August 31, 2018, and should be read in conjunction with them. It is only in the context of the fulsome information and disclosures contained in the unaudited condensed consolidated interim Financial Statements and MD&A that an investor can properly analyze this information.

The Peeks Social app can be downloaded in either the Apple or Google app stores, or by visiting www.peeks.social.

For further information, please contact:

Peeks Social Ltd.
Mark Itwaru
Chairman & Chief Executive Officer
416-639-5339
[email protected]
David Vinokurov
Director Investor Relations
416-716-9281
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed or accepts responsibility for the adequacy or accuracy of this Release. 

Good Life Networks Inc. $GOOD.ca Enters the Video Game Industry with #Programmatic Technology $ATVI $TTWO $GAME $EPY.ca $TCEHF $Game.ca $EPY.ca

Posted by AGORACOM-JC at 8:37 AM on Wednesday, October 31st, 2018

Glnlogo black 11

  • Entered into an agreement AMPD Holdings Corp
  • To provide the Company’s programmatic advertising technology to Gaming industry
  • AMPD specializing in Game Technologies and is the only company in Canada specifically focused on providing technology solutions for game developers and publishers

VANCOUVER, Oct. 31, 2018 – Good Life Networks Inc. (“GLN“, or the “Company“) (TSXV: GOOD) (FSE: 4G5), a programmatic advertising technology company, announced today that it has entered into an agreement (the “Agreement”) AMPD Holdings Corp (dba AMPD Game Technologies), (“AMPD“) to provide the Company’s programmatic advertising technology to the Gaming industry. AMPD is a Vancouver company that specializes in Game Technologies and is the only company in Canada specifically focused on providing technology solutions for game developers and publishers.

“This agreement with AMPD is a first for us in the gaming sector,” said Jesse Dylan, CEO of GLN. “We will help game producers better monetize their user base, while accessing an entire segment of people that are otherwise unavailable to advertisers. This sector could represent millions of incremental ad impressions to our platform annually.”

Anthony Brown, CEO of AMPD commented, “Adding GLN’s advertising technology to our infrastructure will be a game changer. Game studios and infrastructure clients can use the GLN technology to quickly and easily add premium quality advertising to their games at the click of a button.”

AMPD’s partners include Microsoft Corporation, Lenovo Group Ltd, VMware and Dell EMC

The GLN Story

GLN is a patent pending machine learning programmatic video advertising technology company that does not collect PII (Personal Identifiable Information).  GLN serves millions of online video ads daily 3 times faster than IAB (Interactive Advertising Bureau) standards through multiple server to server integrations with both publishers and advertisers. GLN is headquartered in Vancouver, Canada with offices in the US and UK.

Digital ad revenue rose by 16.8%, more than double TV’s in January of 2018 according to Forbes Magazine.

GLN trades on the TSX Venture Exchange under the stock symbol “GOOD” and The Frankfurt Stock Exchange under the stock symbol 4G5.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements:

Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of GLN. This information and these statements, referred to herein as “forward‐looking statements”, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to AMPD. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. Important factors that may cause actual results to vary include without limitation, risks relating to Gaming Industry, AMPD and general economic conditions. In making the forward‐looking statements in this news release, the Company has applied several material assumptions, including without limitation that the AMPD implementation will be successfully completed in the time expected by management and its commercial agreement with AMPD will produce the desired results, generate the anticipated revenue and expand GLN’s global reach per management’s expectations. GLN does not assume any obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements, other than as required by applicable securities laws. Additional information identifying risks and uncertainties is contained in GLN’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

SOURCE Good Life Networks Inc.

View original content: http://www.newswire.ca/en/releases/archive/October2018/31/c2974.html